Exchange: NASDAQ·Updated 07:30 PM EST
VSTM logo

VSTM Verastem Inc

$6.39
$0.53
(7.73%)
Today
Closed $6.33
$0.06
(0.95%)
After Hours
Reported EarningsNov 5
Mkt Cap$797.67M
Vol3.25M

About VSTM

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
42

Bearish Sentiment

How do you feel about VSTM?

Timster118
$VSTM Not sure if this was already posted : In late September 2026, Verastem Oncology received the 2026 Industry Innovator Rare Impact Award from the National Organization for Rare Disorders (NORD). The award was presented by NORD CEO Pamela Gavin to Verastem's leadership team during the week leading up to Rare Cancer Day (which takes place on September 30), to celebrate their innovation and therapeutic advancements for patients with rare ovarian cancer
14
NYBomba
$VSTM - strong uptrend chart and 150 & 200 DMA crossing tomorrow which completes the Golden Cross.... chart, fundamentals and projections are all strong BULLS, no need to fret over daily price fluctuation ...
14
CrozrX
$VSTM 🔥q2 NDA PDAC 2ND line. Pachter is now publicly describing two possible regulatory outcomes from the randomized Phase 2 design. That creates several possibilities: •Monotherapy qualifies for accelerated approval independently. •The combination produces stronger efficacy and supports a separate accelerated-approval application or indication. •The randomized comparison helps establish the contribution of cetuximab while simultaneously informing the frontline Phase 3 strategy.
11
JohnBiotech
$VSTM a lot of nerves in this chat, but I can understand. I will provide some more scientific thoughts tonight after work if anyone is interested.
9
CrozrX
$VSTM $ERAS $RVMD 2 CR PDAC monotherapy with VS-7375, 3rd and 4th line. One appeared approximately three months into treatment, the other around six months, despite multiple prior lines of therapy. Next time you hear Kauffman bringing this up, so you know why! Daraxonrasib monotherapy 1 CR in 2nd L disease. A swimmer plot isn't reserved for extraordinary responses. It's a tool for understanding how treatment activity evolves. Erasca provided one yesterday. Only RVMD didn't, unless i missed it? With 18.3 months of median follow-up and five confirmed CRs in the daraxonrasib + GnP cohort, a patient-level swimmer plot illustrating response onset, evolution and persistence would be particularly informative.
5
Stoltz13
$VSTM nobody cares about earnings today. They're just dropping the price here to get their hands on your shares, simply taking advantage of today's miserable market.
8
Vanderm98
$VSTM I’m no chartist, but it kinda looks like we’re approaching a triple top around 10.5 and then a double at 12.5. Will be interesting to see if we smash through. Revenues make it a decent set up. Let’s ride. GL
1
5
JohnBiotech
$VSTM this is heading back to the high $4 range because of forced selling. Thesis is not broken for VS-7385
5
JohnBiotech
$VSTM it’s been a rough month, but I do not believe any of it is related to our data, or RAS in general. There is no escaping macro, the AI hype, and algo trading. At the end of the day, if funds need to cover losses, riskier assets are some of the first to be sold automatically. Although our data is great so far, there is still substantial risk in drug development. Shorting biotechs is profitable when there is no news. Now that it’s been a month since the data release, I’m not surprised that the short float is high again (especially after dilution too). However, I’d like to discuss the NSCLC oral on Dec 5th: VS-7375 received an oral LBA presentation acceptance at the North America Conference on Lung Cancer. This is important because LBAs set the bar for acceptances higher than a poster. However, this does not automatically mean the data will be spectacular (1/6)
1
3
Crivit
$VSTM 11/6/2026 Royal Bank Of Canada Lower Target OUTPERFORM $19.00 ➝ $18.00 11/6/2026 HC Wainwright Boost Target BUY $18.00 ➝ $20.00
1
4
Teddy313
$VSTM Miss doesn’t mean a thing nothing. Big numbers are years away. Drugs that work are the only thing that matters now.
7
LabPsycho
$VSTM IMO, The shameless greed of an offering right after an offering likely going to throw a very wet and heavy blanket on this thing for a while. Why bother getting a drug approved that even after 10's of millions in sales, the company still loses money when one can just print $100 million, $250 million - $350 million out of thin air! Think about - will any of their drugs (or most early stage biotech drugs) ultimately generate this kind of PROFIT in a year!? Think about the effort and resources required to generate that size profit ($ Hundreds of millions in PROFIT) from an approved drug sales vs just fire up the Offering with a few mouse clicks to your favorite investment banks with ready to go automated templates/ disclaimers to print zillions of new shares for sale - who cares about existing shareholders. Maybe $9 total worth of compute time? Anyhow, VSTM is free to use parts of my video on VS-7375-like molecules to jazz it up a bit - show some real forward thinking science.
1
2
Valueforall
Dont be worried - embrce it. Once you have battle scars after years and years of bio you love to buy more lower, longer......Its just what it is. You do your due diligence. Hold conviction and disconnect yourself from the fluctuations of the price action. I know this. Durso will do a deal and partner or get this sold. maybe not for the price you expect or want (see ICPT) but getting this closer to ground zero makes the fookery less and less possible. My Goal is 5$ I started buying in the high $3's and just added lower and lower, buffering by writing calls against the position. I will keep adding as they want to bring this lower but ultimately the day I sell it will be at a multiple of where it is here. I have so many situations of such cases. SOOOOOOO MAAAAAAAANNNNNNY. I will rattle one off. I bought $VSTM from $4 all the way down to the most somber day of $2.5 and unloaded half from $9-10. Not every train leaves the station at the same time. Paytience
1
2
CrozrX
$VSTM $ERAS An interesting comparison, but the numerator and denominator deserve equal attention, including what remains outside the headline. VS-7375 reported 41% confirmed ORR (9/22) across 2L–4L KRAS G12D PDAC at 900 mg, including 50% (4/8) in exclusively second-line patients. Its modified intent-to-treat (mITT) analysis retained two patients who had not reached their first tumor assessment in the denominator. All nine objective responses were confirmed. Erasca's April analysis pooled US and Chinese efficacy data while reporting detailed safety from the US cohort. Its July update provided a US-only signal of 57% eight-week unconfirmed-inclusive ORR (4/7) at 32 mg in 2L+ KRAS G12X PDAC, not an exclusively G12D population. Lim's competitive framing moves between pooled and US-only datasets, across-dose G12D estimates and broader KRAS G12X populations, while citing VS-7375's overall 41% confirmed ORR rather than its 50% confirmed second-line result.
5
Not12bow
$VSTM continuations of trials demonstrating great results! Investor community increasingly taking notice.
5
Alt_Fuel
$VSTM Official STOCKTWITS Representative https://stocktwits.com/StocktwitsEarnings/message/668197110 $RVMD Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.90 down -18.01% YoY • Reported revenue of $197.56M • Revolution Medicines expects product revenue to increase in future periods because Q3 2026 reflected partial-quarter sales; it expects research and development and selling, general and administrative expenses to increase for the foreseeable future. Bullish Takeaway Bearish Takeaway For the three months ended September 30, 2026, two individual customers accounted for 71% and 28% of Revolution Medicines net product revenue; as of September 30, 2026, two customers accounted for 72% and 28% of accounts receivable. Revolution Medicines relies on third parties to manufacture commercial RASONQUE supply, and some suppliers are currently sole sources; qualifying an alternative supplier could take a substantial period of time, during which commercial supply could be interrupted.
1
2
EmSol
$VSTM early stage for sure but I will not be surprised to see a BO coming, so many big player miss the boat with $RVMD and can’t buy anymore they will be happy to buy a competitor for 5-6 B versus 50B at Rvmd. Still long on $RVMD but like the beat here
5
dl42
$VSTM interesting last 2 days, opens up down and fights all day to go green, Seems like a good thing🤷🏻‍♂️
5
Always_neutral
$VSTM Okay, I think I figured out what caused the shake out during the last two weeks: - Biotech was generally down but that did not explain unusual take down of vstm and RVMD. - Today Adam Feuerstein disclosed that Erasca is presenting updated data in Spain tomorrow. This could be the reason. - At "4handle" PDAC in second line it may not surpass VS7375 for g12d patients but uncertainties took down the price, I believe. - If ERAS-0015 is actually 40%ish ORR, it actually bode well for VSTM. I may be speculating but that is only reasonable take I have.
3
VolumeSpreadAnalysis
$VSTM Price: $10.04 Volume: Above average Catalyst: Recent pipeline update on avutometinib combo data has traders revisiting the name. Resistance: $11.50 Support: $9.20 Bull case: A clean break above $11.50 on strong volume could spark a momentum run toward recent highs. Bear case: Failure to hold $9.20 support could send shares sliding back into the prior consolidation range. What I'm watching: Watching for a volume-confirmed close above resistance or a breakdown below support for directional clues. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio:
4

Advertisement|Remove ads.